Excited about what is to come. Stay tuned. Lots of amazing initiatives in store. Continue to follow @MedNewsWeek on all of our platforms.

🚨 What if we could move beyond “watch and wait” and fundamentally rethink first-line therapy for indolent B-cell lymphomas? Join us for the next episode of MedNews Week Medical Spotlight featuring Paolo Strati, one of the world's leading experts in lymphoma immunotherapy and cellular therapy. Dr. Strati serves as: • Deputy Section Chief for Indolent B-Cell Lymphomas • CARTOX Program Leader • Internationally recognized investigator in lymphoma therapeutics In this masterclass, Dr. Strati will discuss the emerging role of AR² therapy and how novel treatment strategies are reshaping the frontline management of indolent B-cell lymphomas. Topics include: 🔹 Evolution of first-line treatment paradigms 🔹 Clinical data supporting AR² therapy 🔹 Patient selection and practical implementation 🔹 Future directions in lymphoma care Whether you're a hematologist, oncologist, trainee, advanced practitioner, researcher, or patient advocate, this is a discussion you won't want to miss. 📺 youtube.com/watch?v=YXVSavaK… #Lymphoma #Hematology #Oncology #Immunotherapy #CellTherapy #MedicalEducation #MedTwitter #HemOnc #CancerResearch #MDAnderson #BCellLymphoma @MedNewsWeek

One of the most rewarding parts of MedNews Week is watching talented individuals grow and find their voice. It's been wonderful to see your development Adeena over the past several months and the impact you've already made through education, research, and community building. Thank you for your dedication to our mission and for everything you contribute to the team. Excited to see what the future holds for you. The journey is just getting started!

🧬 The conversation around indolent B- cell lymphoma is evolving. For decades, "#watch and #wait" has been the standard approach. Emerging data on #AR² therapy are challenging long-held assumptions and raising important questions about the future of first- line treatment.

Congrats, @YLeyfman !!

I’m deeply honored and humbled to receive the 2026 ASCO Conquer Cancer Merit Award and to represent our work at ASCO Breakthrough 2026 in Singapore. But this recognition is not mine alone. It reflects the countless hours, sacrifices, resilience, and belief of the entire MedNews Week family. Behind every milestone are people who chose to build something bigger than themselves — a mission centered on connecting medicine globally through education, collaboration, and innovation. As MedNews Week celebrates its 4.5-year anniversary, I’m reminded that none of this would have been possible without the extraordinary physicians, researchers, scientists, and global leaders who believed in our vision early on and entrusted us with their voices and stories. To every speaker who has contributed their time, expertise, and passion to educate our global audience — thank you. You helped shape MedNews Week into the platform and community it is today. Success never happens in a vacuum. I’m incredibly grateful to work alongside a team that has become far more than colleagues over the years. MedNews Week was built through shared vision, trust, and the dedication of individuals across the world committed to advancing global medical education. I want to especially thank my mentors, Dr. Chandler Park and Dr. Arturo Loaiza-Bonilla, whose guidance, belief, and unwavering support continuously challenged me to dream bigger, work harder, and never stop growing. Your mentorship has shaped not only my career, but the leader and physician I strive to become. I’m also grateful for the opportunity to collaborate with outstanding colleagues such as Dr. Connor Yoast, whose future in oncology is exceptionally bright, and to the remarkable student and trainee leadership teams whose dedication behind the scenes continues to inspire me every day. Finally, thank you to Dr. Julie Gralow, Dr. Chua, and the entire ASCO Breakthrough team for creating such a meaningful international platform dedicated to innovation, collaboration, and progress in oncology. I’m honored to be part of this year’s meeting and look forward to learning from and connecting with inspiring global leaders from around the world. This is only the beginning. Looking forward to continuing to grow together.

🎥 Watch the full episode here: youtube.com/watch?si=3xZCdD5… @stanfordimmuno @StanfordHeme @StanfordBMT_CT @Stanford @LMikkMD @StanfordMed @CParkMD @oncodaily @OncoDailyIO @Innov_Medicine @Cancers_MDPI @MDPIOpenAccess @jeremy02766919 @MedNewsWeek

🧬✨ A conversation is now live on #MedicalSpotlight — and it opens up a bigger question: How do we move from promising science ➜ meaningful patient impact? 👀👇 🔗: youtu.be/e29SDlFr0qo?si=dKu0…

🧫Blood cancer advanced treatment: Dr. Lekha Mikkilineni, Stanford Medicine, MD, discussed next-generation #CART -cell therapy in #MultipleMyeloma . Watch how advanced cellular therapies are redefining #cancer care on @MedNewsWeek x @OncLive youtube.com/watch?v=e29SDlFr…

We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/lekha-m…

Lekha Mikkilineni Discussed Next-Generation CART-cell Therapy in Multiple Myeloma on MedNewsWeek @LMikkMD @MedNewsWeek oncodaily.com/voices/lekha-m…

Welcome to the MedNews Week leadership team, Dr. Zara Baloch! We are excited to have you join our growing global community and look forward to the many contributions you will make in education, research, and scientific communication. The best is yet to come.

We are thrilled to welcome Dr. Zara Baloch to the MedNews Week leadership team as our Digital Education Manager and Director of Quantitative Research & Meta-Analysis. Dr. Baloch brings tremendous talent, vision, and dedication to advancing medical education, research, and scientific communication. Her passion for evidence synthesis, quantitative research, and community engagement will play an important role as we continue expanding our global impact. At MedNews Week, we believe in investing in exceptional people, and we are excited to watch Dr. Baloch grow as a leader while helping elevate our educational and research initiatives to new heights. We look forward to seeing her contributions showcased through impactful research, international collaborations, major scientific meetings, and peer-reviewed publications. Welcome to the team, Dr. Baloch. The future is bright, and we are excited to have you as part of the MedNews Week family. #MedNewsWeek #Oncology #MedicalEducation #Research #Leadership #GlobalHealth @MedNewsWeek

Dr. @TonyMok9 at #ASCO26 presents update on CROWN in ALK NSCLC. After 7y, median PFS with lorlatinib still not reached. Between years 5 and 7, only 4 progression events occurred. Unusual but fantastic to see such a tail with targeted therapy - this is truly raising the bar.

What a unique opportunity to meet with the Presidents of the @SMEOMX (@anelcabrera), @KSMO_INTL (Prof Kim) & @JSMO_official (Prof Yoshino). Terrific conversations about the status of global research at #ASCO26, aligning with the exciting theme of @ASCO President Eric Small! @ASCOPres @jrgralow

TALAPRO-3 adds another important layer to mHSPC treatment. @neerajaiims Happy to be one of the investigators in this global effort. @AnkaraUni 🇹🇷 🧬Talazoparib enzalutamide ADT improved rPFS vs enzalutamide ADT. ⚠️But benefit must be weighed against toxicity and immature OS. ❓The patient question: Who truly needs PARP intensification upfront? #ASCO26 @NEJM @APCCC_Lugano @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

Opening Day 2 with GU oral abstract session, @SrikalaSridhar sets the stage with “New Approaches to Curing Bladder and Kidney Cancer: Where Do We Stand Today?” an exciting overview of evolving perioperative and biomarker-driven strategies across RCC and urothelial cancer. #ASCO26 #RCC #BladderCancer @OncoAlert @ASCO @OncBrothers

Perioperative EV pembo vs cystectomy (KN905) in MIBC shows great OS & pCR >50%. Quality of life data can be difficult to interpret due to multiple tools & different time points for analysis. Results did not show differences in the 2 arms at week 18 time point. Cystectomy had a more dramatic effect on QOL rather than EVP, but EVP will have both short term and long term side effects. While the methods used here are standard and well presented it feels there maybe a better way of assessing QOL. #ASCO26

#JamesLarkin presents RAMPART, the first phase III trial comparing PD-L1 blockade vs PD-L1/CTLA4 vs surveillance in adjuvant RCC. While only durvalumab tremelimumab met the DFS endpoint, outcomes with durvalumab alone were numerically similar, particularly in clear cell disease, with benefit appearing enriched in higher-risk pts. A question to be raised is whether the lack of formal significance with monotherapy may in part reflect more limited power relative to KEYNOTE-564. #ASCO26 #RCC @OncoAlert @ASCO @OncBrothers